Company: MYGN
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0000899923-25-000048
Chunk: 18

Company: MYRIAD GENETICS INC
Filing Date: 2025-05-07
Form: 10-Q
Item: Part I, Item 1
Chunk 18
---
 amounts)

Three months endedMarch 31,20252024Revenue$195.9 $202.2 Cost of revenue61.7 64.6 Gross profit134.2 137.6 Costs and expenses:Research and development expense27.5 24.9 Sales and marketing expense69.2 69.4 General and administrative expense66.5 71.2 Total operating expenses163.2 165.5 Operating loss(29.0)(27.9)Other income (expense):Interest income0.3 0.6 Interest expense(0.8)(0.5)Other0.1 1.9 Total other income (expense), net(0.4)2.0 Loss before income tax(29.4)(25.9)Income tax (benefit) expense(29.3)0.1 Net loss$(0.1)$(26.0)Net loss per share:Basic and Diluted$— $(0.29)Weighted average shares outstanding:Basic and Diluted91.4 89.9 

See accompanying notes to Condensed Consolidated Financial Statements.

5

Table of Contents

 MYRIAD GENETICS, INC.

AND SUBSIDIARIES

Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited)

(in millions)

Three months endedMarch 31,20252024Net loss$(0.1)$(26.0)Change in unrealized loss on available-for-sale debt securities, net of tax— 0.1 Change in foreign currency translation adjustment, net of tax0.2 (1.3)Reclassification of cumulative translation adjustment to income upon sale or liquidation of certain foreign entities, net of tax— 0.7 Comprehensive income (loss)$0.1 $(26.5)

See accompanying notes to Condensed Consolidated Financial Statements.

6

Table of Contents

MYRIAD GENETICS, INC.

AND SUBSIDIARIES

Condensed Consolidated Statements of Stockholders’ Equity (unaudited)

(in millions)

CommonstockAdditionalpaid-incapitalAccumulatedothercomprehensivelossAccumulateddeficitMyriad Genetics, Inc.Stockholders’equityBALANCES AT DECEMBER 31, 2023$0.9 $1,415.5 $(3.7)$(629.5)$783.2